Estadístiques de Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer
Visites totals
| views | |
|---|---|
| Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer | 196 |
Visites totals per mes
| views | |
|---|---|
| May 2025 | 0 |
| June 2025 | 0 |
| July 2025 | 0 |
| August 2025 | 0 |
| September 2025 | 0 |
| October 2025 | 0 |
| November 2025 | 0 |
Visites al fitxer
| views | |
|---|---|
| scheeweis-ing-pha.pdf(legacy) | 205 |
| scheeweis-ing-pha.pdf | 76 |
Vistes principals per país
| views | |
|---|---|
| United States | 168 |
| Belgium | 8 |
| Germany | 4 |
| Spain | 3 |
| Ireland | 2 |
| Mexico | 2 |
| Australia | 1 |
| Iran | 1 |
| Malaysia | 1 |
| Poland | 1 |
| Russia | 1 |
| Slovenia | 1 |
| Ukraine | 1 |
Visites principals per ciutat
| views | |
|---|---|
| Ashburn | 47 |
| Fairfield | 36 |
| San Ramon | 22 |
| Cambridge | 13 |
| Menlo Park | 9 |
| Ann Arbor | 6 |
| Boardman | 6 |
| Seattle | 4 |
| Jacksonville | 2 |
| Mountain View | 2 |
| Barcelona | 1 |
| Brooklyn | 1 |
| Cancún | 1 |
| Dearborn | 1 |
| Fremont | 1 |
| Magdeburg | 1 |
| Mexico | 1 |
| Mokelumne Hill | 1 |
| Pauls Valley | 1 |
| Phoenix | 1 |
| Premiá De Mar | 1 |
| Shah Alam | 1 |